News >

Dual Transplant Prevails in Patients With Newly Diagnosed Myeloma

Published: Monday, Dec 19, 2016

Michele Cavo, MD

Michele Cavo, MD

Patients with newly diagnosed multiple myeloma had significant improvement in progression-free survival (PFS) when treated with dual versus single autologous stem-cell transplant (ASCT), preliminary results of a randomized trial showed.

 

References

  1. Cavo M, Salwender H, Rosiñol L, et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies. Blood. 2013;122(21):767.
  2. Kenneth AC, Alsina M, Atanackovic D, et al. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015;13(11):1398-1435.
  3. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962. doi: 10.1182/blood-2016-01-631200.
  4. Cavo M, Beksac M, Dimopoulos M, et al. Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial). Presented at: ASH 58th Annual Meeting; December 5, 2016; San Diego, CA. Abstract 673.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x